659 related articles for article (PubMed ID: 10580431)
1. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
2. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
7. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
9. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
[TBL] [Abstract][Full Text] [Related]
10. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
Strowig SM; Avilés-Santa ML; Raskin P
Diabetes Care; 2002 Oct; 25(10):1691-8. PubMed ID: 12351463
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
Suter SL; Nolan JJ; Wallace P; Gumbiner B; Olefsky JM
Diabetes Care; 1992 Feb; 15(2):193-203. PubMed ID: 1547676
[TBL] [Abstract][Full Text] [Related]
14. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Ciaraldi TP; Kong AP; Chu NV; Kim DD; Baxi S; Loviscach M; Plodkowski R; Reitz R; Caulfield M; Mudaliar S; Henry RR
Diabetes; 2002 Jan; 51(1):30-6. PubMed ID: 11756319
[TBL] [Abstract][Full Text] [Related]
15. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
17. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Ghazzi MN; Perez JE; Antonucci TK; Driscoll JH; Huang SM; Faja BW; Whitcomb RW
Diabetes; 1997 Mar; 46(3):433-9. PubMed ID: 9032099
[TBL] [Abstract][Full Text] [Related]
18. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy.
Miles JM; Wooldridge D; Grellner WJ; Windsor S; Isley WL; Klein S; Harris WS
Diabetes; 2003 Mar; 52(3):675-81. PubMed ID: 12606508
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
